New hope for melanoma patients when standard immunotherapy fails
NCT ID NCT04971499
Summary
This study is testing whether adding an experimental drug called dapansutrile to the standard immunotherapy pembrolizumab can help patients with advanced melanoma whose cancer has stopped responding to PD-1 drugs alone. The trial has two parts: first finding the safest dose, then testing how well the combination works. It's for adults with advanced melanoma that has continued to grow despite previous immunotherapy treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.